Paper42345003
Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.
Ensina LF and 5 others. J Inflamm Res, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria. Papers, record 42345003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42345003
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28543019 | The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. | Allergy | 2017 | https://conductscience.org/library/papers/28543019 | PubMed |
| 2 | 31332983 | Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review. | Allergy Asthma Immunol Res | 2019 | https://conductscience.org/library/papers/31332983 | PubMed |
| 3 | 39490777 | Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: Evolving toward personalized medicine. | Ann Allergy Asthma Immunol | 2025 | https://conductscience.org/library/papers/39490777 | PubMed |
| 4 | 34650565 | What Basophil Testing Tells Us About CSU Patients - Results of the CORSA Study. | Front Immunol | 2021 | https://conductscience.org/library/papers/34650565 | PubMed |
| 5 | 36241154 | Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring. | J Allergy Clin Immunol Pract | 2022 | https://conductscience.org/library/papers/36241154 | PubMed |
| 6 | 33496195 | Biomarkers of chronic spontaneous urticaria and their clinical implications. | Expert Rev Clin Immunol | 2021 | https://conductscience.org/library/papers/33496195 | PubMed |
| 7 | 35928809 | STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. | Front Immunol | 2022 | https://conductscience.org/library/papers/35928809 | PubMed |
| 8 | 26483177 | Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. | J Allergy Clin Immunol | 2016 | https://conductscience.org/library/papers/26483177 | PubMed |
| 9 | 30355455 | Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria. | Allergol Int | 2019 | https://conductscience.org/library/papers/30355455 | PubMed |
| 10 | 38433976 | D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/38433976 | PubMed |
| 11 | 20626384 | Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. | Allergy | 2010 | https://conductscience.org/library/papers/20626384 | PubMed |
| 12 | 36448493 | Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. | Allergy | 2023 | https://conductscience.org/library/papers/36448493 | PubMed |
| 13 | 38431226 | Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. | J Allergy Clin Immunol | 2024 | https://conductscience.org/library/papers/38431226 | PubMed |
| 14 | 40756290 | A 10-Year Real-World Analysis of Omalizumab Use in Chronic Spontaneous Urticaria Patients at a Dermatology Clinic. | Sisli Etfal Hastan Tip Bul | 2025 | https://conductscience.org/library/papers/40756290 | PubMed |
| 15 | 24522090 | Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. | J Allergy Clin Immunol | 2014 | https://conductscience.org/library/papers/24522090 | PubMed |
| 16 | 11240971 | Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. | Clin Pharmacol Ther | 2001 | https://conductscience.org/library/papers/11240971 | PubMed |
| 17 | 31494963 | Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. | Allergy | 2020 | https://conductscience.org/library/papers/31494963 | PubMed |
| 18 | 41005705 | Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. | J Allergy Clin Immunol Pract | 2025 | https://conductscience.org/library/papers/41005705 | PubMed |
| 19 | 40682223 | Biomarkers of response to omalizumab in patients with chronic spontaneous urticaria. | Allergol Immunopathol (Madr) | 2025 | https://conductscience.org/library/papers/40682223 | PubMed |
| 20 | 35853771 | Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes? | An Bras Dermatol | 2022 | https://conductscience.org/library/papers/35853771 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IGHE | 3497 | PubTator's text mining | https://conductscience.org/library/genes/3497 | NCBI Gene |
| KIT | 3815 | PubTator's text mining | https://conductscience.org/library/genes/3815 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42345003
GET https://conductscience.org/api/papers/v1/42345003/references?page=2